Scott Wardwell

5.8k total citations · 1 hit paper
22 papers, 2.4k citations indexed

About

Scott Wardwell is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Scott Wardwell has authored 22 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Pulmonary and Respiratory Medicine and 7 papers in Oncology. Recurrent topics in Scott Wardwell's work include Lung Cancer Treatments and Mutations (6 papers), Chronic Myeloid Leukemia Treatments (5 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Scott Wardwell is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Chronic Myeloid Leukemia Treatments (5 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Scott Wardwell collaborates with scholars based in United States and Switzerland. Scott Wardwell's co-authors include Victor M. Rivera, Tim Clackson, Frank Wang, Wei Fang, J. J. McDowell, Tara Seshadri, Ping Li, Michael Paskind, Jochen Salfeld and Daniel E. Tracey and has published in prestigious journals such as Science, Cell and Blood.

In The Last Decade

Scott Wardwell

22 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mice deficient in IL-1β-converting enzyme are defective in production of mature IL-1β and resistant to endotoxic shock

1995 1.2k citations Ping Li, Hamish Allen et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Scott Wardwell United States	15	1.6k	644	386	354	241	22	2.4k
Anthony Simon Israel	34	1.8k 1.1×	970 1.5×	371 1.0×	302 0.9×	192 0.8×	111	3.3k
Raffaella Soldi United States	26	1.8k 1.1×	466 0.7×	454 1.2×	253 0.7×	185 0.8×	53	2.8k
Jean‐Philippe Salier France	27	1.1k 0.7×	420 0.7×	299 0.8×	174 0.5×	206 0.9×	66	2.4k
Charles Perkins United States	22	1.2k 0.8×	753 1.2×	399 1.0×	195 0.6×	576 2.4×	35	2.7k
Martin S. Staege Germany	23	1.4k 0.9×	842 1.3×	669 1.7×	356 1.0×	102 0.4×	108	2.7k
Ruth W. Craig United States	29	2.3k 1.5×	734 1.1×	965 2.5×	215 0.6×	318 1.3×	44	3.3k
Yaël Zermati France	18	1.6k 1.0×	687 1.1×	282 0.7×	149 0.4×	427 1.8×	24	2.6k
Susanna C. Fagerholm Finland	23	962 0.6×	1.0k 1.6×	327 0.8×	141 0.4×	161 0.7×	49	2.6k
K R Auger United States	16	1.5k 0.9×	879 1.4×	511 1.3×	121 0.3×	151 0.6×	22	2.7k

Countries citing papers authored by Scott Wardwell

Since Specialization

Citations

This map shows the geographic impact of Scott Wardwell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Wardwell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Wardwell more than expected).

Fields of papers citing papers by Scott Wardwell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Wardwell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Wardwell. The network helps show where Scott Wardwell may publish in the future.

Co-authorship network of co-authors of Scott Wardwell

This figure shows the co-authorship network connecting the top 25 collaborators of Scott Wardwell. A scholar is included among the top collaborators of Scott Wardwell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott Wardwell. Scott Wardwell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schalm, Stefanie S., John Campbell, Jian Guo, et al.. (2022). Abstract 3328: Antitumor activity of BLU-945 and BLU-701 as single agents and in combination in EGFR L858R-driven models of NSCLC. Cancer Research. 82(12_Supplement). 3328–3328. 9 indexed citations

Gozgit, Joseph M., Youngchul Song, Scott Wardwell, et al.. (2018). RET fusions observed in lung and colorectal cancers are sensitive to ponatinib. Oncotarget. 9(51). 29654–29664. 19 indexed citations

Zhang, Sen, Sara Nadworny, Scott Wardwell, et al.. (2015). Abstract 781: The potent ALK inhibitor AP26113 can overcome mechanisms of resistance to first- and second-generation ALK TKIs in preclinical models. Cancer Research. 75(15_Supplement). 781–781. 9 indexed citations

Huang, Wei‐Sheng, Feng Li, Lisi Cai, et al.. (2015). Abstract 2827: Discovery of AP26113, a potent, orally active inhibitor of anaplastic lymphoma kinase and clinically relevant mutants. Cancer Research. 75(15_Supplement). 2827–2827. 2 indexed citations

Garner, Andrew P., Joseph M. Gozgit, Rana Anjum, et al.. (2014). Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients. Clinical Cancer Research. 20(22). 5745–5755. 123 indexed citations

Gozgit, Joseph M., Rachel M. Squillace, Matthew Wongchenko, et al.. (2013). Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. Cancer Chemotherapy and Pharmacology. 71(5). 1315–1323. 50 indexed citations

Gozgit, Joseph M., Matthew J. Wong, Lauren Moran, et al.. (2012). Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models. Molecular Cancer Therapeutics. 11(3). 690–699. 273 indexed citations

Squillace, Rachel M., David F. Miller, Scott Wardwell, et al.. (2012). Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. International Journal of Oncology. 41(2). 425–432. 27 indexed citations

Rivera, Victor M., Frank Wang, Rana Anjum, et al.. (2012). Abstract 1794: AP26113 is a dual ALK/EGFR inhibitor: Characterization against EGFR T790M in cell and mouse models of NSCLC. Cancer Research. 72(8_Supplement). 1794–1794. 36 indexed citations

10.

Squillace, Rachel M., David F. Miller, Scott Wardwell, et al.. (2011). Antitumor Activity of Ridaforolimus and Potential Cell-Cycle Determinants of Sensitivity in Sarcoma and Endometrial Cancer Models. Molecular Cancer Therapeutics. 10(10). 1959–1968. 40 indexed citations

11.

Rivera, Victor M., Rachel M. Squillace, David F. Miller, et al.. (2011). Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens. Molecular Cancer Therapeutics. 10(6). 1059–1071. 87 indexed citations

12.

Gozgit, Joseph M., Matthew J. Wong, Scott Wardwell, et al.. (2011). Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies. Molecular Cancer Therapeutics. 10(6). 1028–1035. 110 indexed citations

13.

Zhang, Sen, Frank Wang, Jeffrey Keats, et al.. (2010). Abstract LB-298: AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066). Cancer Research. 70(8_Supplement). LB–298. 44 indexed citations

14.

Wardwell, Scott, et al.. (2008). 324 POSTER Synergistic activity of the mTOR inhibitor deforolimus (AP23573; MK-8669) and the anti-androgen bicalutamide in prostate cancer models. European Journal of Cancer Supplements. 6(12). 103–103. 1 indexed citations

15.

Corbin, Amie S., Shadmehr Demehri, Ian J. Griswold, et al.. (2005). In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. Blood. 106(1). 227–234. 47 indexed citations

16.

Corbin, Amie S., Shadmehr Demehri, Ian J. Griswold, et al.. (2004). In Vitro and In Vivo Activity of the Src/Abl Kinase Inhibitor AP23464 and Analogs Against Activation Loop Mutants of KIT.. Blood. 104(11). 793–793. 2 indexed citations

17.

Rivera, Victor M., Xiurong Wang, Scott Wardwell, et al.. (2000). Regulation of Protein Secretion Through Controlled Aggregation in the Endoplasmic Reticulum. Science. 287(5454). 826–830. 271 indexed citations

18.

Li, Ping, Hamish Allen, Subhashis Banerjee, et al.. (1995). Mice deficient in IL-1β-converting enzyme are defective in production of mature IL-1β and resistant to endotoxic shock. Cell. 80(3). 401–411. 1225 indexed citations breakdown →

19.

Wardwell, Scott, et al.. (1991). Effect of butyrate and corticosteroids on retinoblastoma in vitro and in vivo.. PubMed. 32(6). 1711–3. 12 indexed citations

20.

Marcus, Dennis M., et al.. (1990). The Value of Nucleolar Organizer Regions in Uveal Melanoma. American Journal of Ophthalmology. 110(5). 527–534. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact